Status:
RECRUITING
Cancer and Immune Cell Metabolism in Patients With Hematological Malignancies
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Hematologic Malignancy
Eligibility:
All Genders
18+ years
Brief Summary
This study investigates how metabolism in cancer and immune cells shapes the bone marrow environment, influences therapy resistance, and affects outcomes in hematological malignancies.
Detailed Description
Hematological malignancies, such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myelofibrosis, are aggressive cancers of the blood and immune system. While chemotherapy is common...
Eligibility Criteria
Inclusion
- age \> 18 years,
- signed written informed consent
- For participants with hematological cancers: diagnosis of MDS, AML, ALL, PMF or post-ET/PV MF
Exclusion
- pregnant or lactating women,
- inability to give consent,
- active malignant disease (other than MDS, AML, ALL, PMF or post-ET/PV MF in the last 3 - years prior to study inclusion).
- For healthy donors: previous or current hematological disease, previous or current other malignant disease,
Key Trial Info
Start Date :
October 29 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2040
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT07189117
Start Date
October 29 2025
End Date
December 1 2040
Last Update
December 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Basel
Basel, Switzerland, 4031